

Contents

1	Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens	1
	Introduction	1
	Testing Methods for Estrogen	2
	Structure-Activity Relationships of Estrogens	3
	Estrogen Action	6
	Nonsteroidal Antiestrogens	7
	Structure-Activity Relationships in the Rat	7
	Substituted Triphenylethylenes	7
	Bicyclic Antiestrogens	9
	The Molecular Modulation of the Estrogen Receptor by Nonsteroidal Antiestrogens	12
	Effect of Antiestrogens in Different Species	16
	Mouse	17
	Rat	18
	Chick	20
	Conclusion	20
	References	22
2	Tamoxifen Goes Forward Alone	31
	Introduction	31
	ICI 46,474: The Early Years	33
	ICI 46,474 to Tamoxifen	37
	Patenting Problems	39
	Conclusion	40
	References	42
3	Metabolites of Tamoxifen as the Basis of Drug Development	47
	Introduction	47
	Basic Mechanisms of Tamoxifen Metabolism	48
	Metabolic Mimicry	52
	Tamoxifen Metabolism Today	55

Clinical Correlations	57
References	60
4 Adjuvant Therapy: The Breakthrough	69
Introduction	69
Adjuvant Therapy with Tamoxifen	70
Studies in Premenopausal Women	73
Overview of Clinical Trials	74
Arrival of Aromatase Inhibitors as Adjuvant Therapy	76
Increasing Survivorship Following 5 Years of Adjuvant Tamoxifen	77
References	80
5 The Wisconsin Story in the 1980s: Discovery of Target Site-Specific Estrogen Action	85
Introduction	85
Laboratory Studies on the Target Site-Specific Pharmacology of “Nonsteroidal Antiestrogens”	86
The Wisconsin Tamoxifen Study	89
Translational Research	90
References	96
6 Carcinogenesis and Tamoxifen	101
Introduction	101
Tamoxifen and the Endometrial Carcinoma	102
Deaths from Endometrial Carcinoma	103
Tamoxifen and the Stage of Endometrial Carcinoma	104
Incidence of Endometrial Cancer with Tamoxifen	105
Tamoxifen and Rat Liver Carcinogenesis	107
Tamoxifen and DNA Adduct Formation	108
Doses of Tamoxifen in Animals and Man	109
Testing at Comparable Therapeutic Levels	110
Conclusion	111
References	113
7 Chemoprevention: Cinderella Waiting for the Ball	115
Introduction	115
The Link Between Estrogen and Breast Cancer	116
Prevention of Mammary Cancer in Rodents	117
Tamoxifen: The First SERM for the Prevention of Breast Cancer in High-Risk Populations	119
Royal Marsden Study	120
NSABP/NCI P-1 Study	122
Italian Study	125
The International Breast Cancer Intervention Study (IBIS-I)	126
Follow-Up of Chemoprevention Studies with Tamoxifen	127

Two Approaches to the Chemoprevention of Breast Cancer	127
Raloxifene: Abandoned and Resurrected	128
Conclusion	131
References	131
8 Tamoxifen and Raloxifene Head to Head: The STAR Trial	135
References	141
9 Acquired Resistance to Tamoxifen: Back to the Beginning	143
Introduction	143
The MCF-7 Breast Cancer Cell Line	144
Tamoxifen Metabolism Hypothesis	145
Growth Factor-Driven Acquired and Intrinsic Resistance	146
An Evolving Model of Acquired Resistance to SERMs and Aromatase Inhibitors	147
Back to the Beginning	149
Mechanisms of Estrogen-Induced Apoptosis	150
A New Classification of Estrogens	152
Final Thoughts on Four Decades of Discovery to Advance the Value of the ER Target in Breast Cancer	153
References	157
10 The Legacy of Tamoxifen	165
Introduction	165
Pure Antiestrogens	166
SERM Successes	168
Lasofoxifene (CP-336156, Fablyn)	169
Bazedoxifene (TSE-424, WAY-140424)	170
Ospemifene (FC-1271a)	170
Refining the SERM Concept Further	171
References	174
Appendix A: Four Decades of Discovery in Breast Cancer Research and Treatment: An Interview with V. Craig Jordan	179
Appendix B: Selected Awards That Recognize the Contribution of Tamoxifen and Raloxifene to Medicine	197

Tamoxifen

Pioneering Medicine in Breast Cancer

Maximov, P.Y.; McDaniel, R.E.; Jordan, V.C.

2013, XXII, 199 p. 54 illus., Hardcover

ISBN: 978-3-0348-0663-3